InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,246.40
(
0.37%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.96
(
0.91%
)
Bitcoin
61,333.53
(
-0.77%
)
Post# of 20775
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

montanus

Send PM Follow Ignore
Followers 13
Posts 1001
Boards Moderated 0
Alias Born 03/12/2009

montanus

Re: None

Sunday, 08/04/2013 4:35:53 PM

Sunday, August 04, 2013 4:35:53 PM

Post# of 20775
PFE - Ponezumab Studies

Rank Status Study

1 Completed Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 1 mg/kg; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 5 mg/kg; Biological: PF-04360365 10 mg/kg

2 Completed Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg; Biological: PF-04360365 0.5 mg/kg; Biological: PF-04360365 1 mg/kg; Drug: Placebo; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 8.5 mg/kg

3 Completed Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 8.5 mg/kg; Drug: Placebo

4 Completed A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo

5 Recruiting Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Condition: Cerebral Amyloid Angiopathy
Interventions: Biological: Ponezumab; Other: placebo

6 Completed Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo

7 Completed A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 10 mg/kg; Biological: PF-04360365 7.5 mg/kg; Drug: placebo

8 Completed A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo

http://clinicaltrials.gov/ct2/results?term=ponezumab&Search=Search


So we have 8 studies with ponezumab and the tech. based on ANTISENILIN platform. No one is interested in ILNS technology?

5 Recruiting Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Condition: Cerebral Amyloid Angiopathy
Interventions: Biological: Ponezumab; Other: placebo

Things that are equal to the same thing are also equal to one another (Transitive property of equality). If equals are added to equals, then the wholes are equal. If equals are subtracted from equals, then the remainders are equal. Things that coincide wi

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up